

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not Yet Assigned
Group Art Unit : Not Yet Assigned
Applicants : Guy W. Bemis, et al.
Application No. : Not Yet Assigned
Filed : Concurrently Herewith
For : INHIBITORS OF INTERLEUKIN-1 β CONVERTING ENZYME

New York, New York
June 21, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the issuance of the first Office Action in the above-identified application,
kindly amend the application as follows:

IN THE CLAIMS

Please cancel claims 1-75, 77-101, 108-117, and 119-124.

Please amend claim 76 as follows:

EXPRESS MAIL
EK708045951US

0988673-063101
"E/498860"

Please amend claim 76 as follows:

76. A method for treating or preventing a disease selected from the group consisting of IL-1 mediated disease, autoimmune disease, inflammatory disease, neurodegenerative disease, and infectious disease in a patient comprising the step of administering to said patient a pharmaceutical composition according to claim 125.

Please add claims 125-127.

125. A pharmaceutical composition comprising a compound according to any one of claims 102-107 or 118 and a pharmaceutically acceptable carrier.

126. A method for promoting wound healing in a patient comprising the step of administering to said patient a pharmaceutical composition according to claim 125.

127. A method for treating or preventing a disease selected from septic shock, septicemia, adult respiratory distress syndrome, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Graves' disease, autoimmune gastritis, insulin-dependent diabetes mellitus, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, chronic active hepatitis, myasthenia gravis, multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, or primary lateral sclerosis in a patient comprising the step of administering to said patient a pharmaceutical composition according to claim 125.

128. The method according to claim 127 wherein the disease is septic shock or rheumatoid arthritis.

REMARKS

Applicants have added claim 125 directed to pharmaceutical compositions.

Applicants have accordingly deleted claims 71-75 directed to pharmaceutical compositions having specific intended uses. Support for added claim 125 may be found throughout the specification as originally filed (see particularly, page 113, lines 17-21) and in claims 71-75 as originally filed.

Applicants have added claims 126-128 to recite methods for administering the compounds and pharmaceutical compositions of this invention. Support for these amendments may be found throughout the specification as originally filed (see particularly, page 116, line 31 to page 117, line 12) and claim 76 as originally filed.

Applicants request consideration of the application and early allowance of the pending claims.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)

Lisa A. Dixon (Reg. No. 40,995)

Attorneys for Applicants

c/o FISH & NEAVE

1251 Avenue of the Americas

New York, New York 10020

Tel.: (212) 596-9000

Fax.: (212) 596-9090

AMENDED CLAIMS MARKED TO SHOW AMENDMENTS

4